相关实验视频

Updated: Jun 19, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

在患有ABCA3缺乏症的儿童中使用环素A

Xiaohua Yang¹, Maria E Forstner¹, Ina Rothenaigner²

¹Dr. von Haunersches Kinderspital, University of Munich, German Center for Lung Research (DZL), Munich, Germany.

Pediatric pulmonology

|July 23, 2024

概括

环素A (CsA) 在患有罕见遗传性肺病ABCA3缺乏症的儿童中显示出改善肺功能的潜力. 需要进一步的临床试验来确认它对这种疾病的有效性.

科学领域:

肺部病理学肺部病理学
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

在ATP结合盒子子子家族A成员3 (ABCA3) 中的双变异会导致严重的儿科间歇性肺病.
对于ABCA3缺陷,目前还没有确定的治疗方法.
试验室研究表明,环素A (CsA) 可能纠正一些ABCA3变异.

研究的目的:

为了研究CSA在患有ABCA3变异的儿童中的临床效果.
从功能上描述两个ABCA3变体 (G210C和Q1045R) 并评估CSA在体外的影响.

主要方法:

获取了两名患有同卵性ABCA3变异的儿童的临床数据,这些儿童接受了CSA治疗.
使用A549细胞进行了体外实验,以鉴定ABCA3变异的特征,并测试CsA+/-氧化 (HCQ).

主要成果:

两个孩子都在CsA上表现出改善的氧化和稳定的肺功能,即使在停止治疗后.
在体外,CsA纠正了ABCA3贩运和囊泡大小缺陷的两个变体.
与HCQ相结合的CsA对G210C变种贩运产生了添加效益.

结论:

对特定的ABCA3缺乏症患者来说,CsA可能会带来治疗效益.
目前支持CSA使用的临床证据有限.
进一步的临床试验对于验证CsA在ABCA3缺乏症中的有效性至关重要.

关键词:

在ABCA3中,ABCA3是ABCA3 ATP结合盒子子子家族A成员3 童年的童年童年的童年循环氨酸A 是一种氧化chloroquine 的使用情况间歇性肺病间歇性肺病

更多相关视频

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Murine Full-thickness Skin Transplantation

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...